Ajit Khaira, MD
Internal Medicine · Fresno, CANPI 1487633764
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.3% of the total across 1,247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $4,555 and has fallen 66.6% since, to $1,522 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,247 payments — averaging $16.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$4K
- Novo Nordisk$3K
- AstraZeneca$2K
- Novartis$1K
- Amarin Pharma, Inc.$1K
- GSK$1K
- plus $7K from 29 others
Across 61 payments — averaging $2626.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$89K
- Novo Nordisk AS$45K
- Astrazeneca UK Limited$24K
- Boehringer Ingelheim$2K
What the payments were for
- Consulting fees$9245%
- Food & beverage$18,94994%
- Education$2271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 203 | $3,698 |
| Novo Nordisk | 219 | $2,777 |
| AstraZeneca | 98 | $2,385 |
| Novartis | 36 | $1,441 |
| Amarin Pharma, Inc. | 128 | $1,421 |
| GSK | 95 | $1,378 |
| Boehringer Ingelheim | 74 | $952 |
| Bayer | 31 | $815 |
| Lilly USA, LLC | 41 | $663 |
| Sunovion Pharmaceuticals Inc. | 36 | $458 |
| AbbVie(2 entities) | 36 | $443 |
| Johnson & Johnson | 18 | $439 |
| Pfizer | 38 | $429 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 31 | $404 |
| Merck | 32 | $394 |
| Mannkind Corporation | 27 | $364 |
| Eisai Inc. | 13 | $263 |
| Biodelivery Sciences International, Inc. | 23 | $242 |
| OPKO Pharmaceuticals, LLC | 19 | $191 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $174 |
| Otsuka America Pharmaceutical, Inc. | 8 | $170 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Arbor Pharmaceuticals, Inc. | 6 | $81 |
| Sumitomo Pharma America, Inc. | 7 | $78 |
| Mylan Specialty L.p. | 2 | $62 |
| Teleflex LLC | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $38 |
| Endo Pharmaceuticals Inc. | 2 | $29 |
| Alkermes, Inc. | 1 | $25 |
| Regeneron Healthcare Solutions, Inc. | 1 | $19 |
| Abbott | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $13 |
| Nevro Corp. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,100 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 490 | $583,402 |
| RybelsusSemaglutide | 236 | $340,360 |
| FarxigaDapagliflozin Propanediol | 221 | $222,738 |
| VascepaIcosapent Ethyl | 308 | $214,594 |
| OzempicSemaglutide | 180 | $186,235 |
| EntrestoSacubitril/Valsartan | 87 | $113,358 |
| TradjentaLinagliptin | 139 | $111,318 |
| TezspireTezepelumab-Ekko | 25 | $101,626 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $94,529 |
| EliquisApixaban | 80 | $89,653 |
| JanuviaSitagliptin Phosphate | 77 | $73,370 |
| XareltoRivaroxaban | 69 | $66,912 |
| LinzessLinaclotide | 93 | $58,460 |
| RexultiBrexpiprazole | 29 | $56,770 |
| Icosapent Ethyl | 177 | $46,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $952 | $694,720629 claims |
| Novo NordiskRybelsus, Ozempic | $2,777 | $526,595416 claims |
| AstraZenecaFarxiga, Tezspire, Breztri Aerosphere | $2,385 | $344,786271 claims |
| NovartisEntresto | $1,441 | $113,35887 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $1,378 | $106,563118 claims |
| MerckJanuvia, Janumet, Steglatro | $394 | $92,389109 claims |
| PfizerEliquis | $429 | $89,65380 claims |
| Johnson & JohnsonXarelto | $439 | $66,91269 claims |
| AbbVieLinzess | $443 | $58,46093 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $170 | $56,77029 claims |
| AmgenProlia | $3,698 | $36,72622 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $78 | $33,23630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Fresno
- John NelsonFresno$413K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.